Activation of antigen-exposed iMC-DCs at the "right place" and "right time" promotes potent anti-tumor immunity.
To better control the "licensing" of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo within the context of an immunological synapse. This novel technology results in potent anti-cancer activity.
Department of Pathology and Immunology; Baylor College of Medicine; Houston, TX USA.
David M
DM
Spencer